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MiRNAs regulate gene expression post-transcriptionally and pre-translationally. Through gene regulation, 
several miRNAs have been found to play a significant role in various diseases. Each miRNA has multiple targets 
and is able to have a potent, albeit complex, effect on the cells. Specifically, miRNA-15a has been found to 
significantly reduce cancer cell survival and aggressiveness through multiple mechanisms across several cancer 
types. Our research found that miRNA-15a was able to decrease melanoma cell viability in-vitro and in-vivo. We 
have also found that miRNA-15a caused cell cycle arrest at the G0/G1 phase. Moreover, miRNA-15a was found to 
decrease the invasiveness of melanoma cells. CDCA4 was also discovered as a novel bona-fide target of 
miRNA-15a. The following oncogenic mRNAs are verified targets of miRNA-15a: CDCA4, BCL2L2, YAP1, 
AKT-3, Cyclin E1, and γ-Synuclein. In the future we hope to better understand which miRNAs will be effective 
in different transcriptome and genome environments. Efforts such as the NIH Center for Cancer Genomics’ 
‘The Cancer Genome Atlas,’ ‘Cancer Target and Driver Discovery Network,’ and the ‘Human Cancer Models 
Initiatives’ among others, will help us characterize the specific tumor environments in which different miRNAs 
are able to reduce cancer proliferation and aggression. This information will be enhanced by improving the 
delivery of miRNA by inducing its expression in-situ with dCas9 conjugated to activation domains. 
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MicroRNA (miRNA, miR) is a 22 nucleotide non-coding 
RNA molecule that regulates translation by binding the 
RNA-Induced Silencing Complex (RISC) with Ago1-2 
(Elf2C1-2), and Gemin3-4 [1-3]. The RISC-miRNA complex 
binds mRNA and inhibits its translation through a variety of 
methods. If the complementary strands of miRNA and 
mRNA are near-identical, nuclease activity is observed by 
Argonaute on the mRNA strand in cytoplasmic "P-bodies" [4, 
5]. This leads to complete degradation of the mRNA and 
inability for it to express its protein. However, even partial 
complementary matches are able to inhibit translation by 
blocking ribosome binding [4]. 
Due to its ability to control cell processes by modulating 
protein expression, miRNA has been studied heavily in order 
to observe its ability to fight disease. Recently, many 
miRNAs have shown promise in being able to modulate the 
behaviors of cancer cells through regulating various target 
mRNAs [6]. In fact, there are currently at least five miRNAs 
or sister-like siRNAs in clinical trials for cancer [7]. It is 
crucial for us to understand the complex interactions of 
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miRNAs, transcription factors, mRNAs, and effector 
proteins. By clarifying these interactions, researchers will be 
able to guide the future of miRNA research and clinical 
applications. 
Different cancer types tend to have characteristic miRNA 
deregulation profiles that can be used to make specific 
treatment plans for individual patients [8]. Several deregulated 
miRNAs have been established in melanoma cells such as 
miR-26a and miR-15a [9, 10]. In breast cancer, the miR-200 
family has shown regulation of tumor progression and 
miR-205 inhibits metastasis [11, 12]. Moreover, colorectal 
cancer metastasis and patient survival have been shown to be 
regulated by miR-184 and miR-133b [13]. Several types of 
cancers are also affected by deregulation of miRNAs that 
control DNA-repair mechanisms [14]. For example, miR-181d 
targets MGMT, which is crucial for DNA repair and several 
miRNAs target DNA repair enzyme inhibitor HGMA2 [15, 16]. 
These are some of the best known miRNA deregulations in 
cancer, but there are more being discovered and validated. 
Not only can we treat these cancer patients with miRNA, but 
we are also able to use miRNA as an oncogenic biomarker 
early detection method and for understanding the mutation 
spectrum of certain cancer populations [17]. 
MiRNA-15a-5p has shown multiple strong roles in 
regulating cancer cells across several cell types. While there 
have been many theoretical targets of miRNAs, it is 
important to make sure they have been properly validated 
before making assumptions on their activity from 
computations alone. With this in mind, we have used only 
evidence-based knowledge to help clarify what is currently 
known about miR-15a activity in cancer. There are several 
pathways that interact together through miR-15a. In fact, 
miR-15a has activity on multiple transcription factors, 
making its role in cancer quite complex. Together, all of the 
effects of miR-15a lead to anti-cancer effects from multiple 
directions, making it an ideal cancer therapy molecule.  
For the US alone, there are an estimated 595,690 deaths 
caused by cancer over the year of 2016 [18]. In the US, 
melanoma is forecasted to consist of 6% of all new cancer 
cases for males and 3% for females as well as result in death 
for 10,130 cancer patients. Effective and safe treatment 
options are still in high demand. One of the most effective 
targeted treatments for melanoma, Vemurafenib in 
combination with Cobimetinib, still only has median 
progression free survival of 9.9 months and 24% of patients 
obtain Cutaneous Squamous Cell Carcinoma as a side-effect 
[19, 20]. Moreover, although interleukin-2 and Ipilimumab 
have recently been credited for their relatively high efficacy 
against melanoma, they still only have a 5-year survival rate 
of 20% [21, 22]. The need for new therapies is prevalent, and 
miRNA is starting to fill that role. 
We have been working to discover the effects of miR-15a 
in malignant melanoma. We have found that miR-15a 
displayed a strong inhibitory effect on cell proliferation, cell 
cycle progression and cell migration of melanoma cells and 
directly targeted CDCA4 [10]. We observed that miR-15a 
transfection significantly decreased the cell viability of four 
different melanoma cell lines: B16-F10, SKMEL-28, A375 
and CRL-2808. Also, miR-15a caused increased percentages 
in the G1/G0 phase and concomitant decrease in cell 
populations in both the S and G2 phases, suggesting that 
miR-15a caused cell cycle arrest at G1/G0 phase.  In 
addition, miR-15a transfection reduced the cell invasion by 
47%, which was displayed by the decreased ability of the 
melanoma cells to invade through the Transwell membrane. 
In vivo, miR-15a significantly retarded the growth of 
melanoma established by melanoma cells that were 
transfected with miR-15a starting at 10 nM. We also 
performed a mechanistic study to discover the mechanism by 
which miR-15a induces these anti-cancer properties. We 
used the TargetScan database to determine highly conserved 
theoretical targets of miR-15a. Putative targets were then 
analyzed through Western Blotting to determine whether 
these targets were down-regulated by miR-15a. We found 
Akt-3 and CDCA4 to both have decreased expressions in 
both the CRL-2808 and SK-MEL-28 cell lines. In order to 
determine the bona-fide target of miR-15a, we used a 
luminescence reporter assay, in which a Gaussia Luciferase 
(GLuc) gene was under the regulation of CDCA4’s 3’ 
untranslated region (UTR) on its 3’ end. While the scramble 
miRNA had no effect on GLuc expression, miR-15a mimics 
successfully inhibited the expression and activity of 
luciferase. Since miR-15a significantly decreased expression 
of the CDCA4 3’ UTR-regulated gene, we conclude that 
miR-15a directly targets the CDCA4 3’ UTR at the 468-475 
highly conserved seed region as determined by TargetScan. 
This experiment was the first elucidation of CDCA4 as a 
direct target of miR-15a. CDCA4 activity has been found to 
be associated with the G1/S phase transition regulation as a 
transcription factor. It is a Trip-Br cofactor, which is known 
to suppress the E2F1 promoter [23]. CDCA4 has also been 
determined to be a transcription factor that plays a role in 
regulating the expression of the JUN oncogene [24]. Our lab is 
currently working on elucidating more functions and 
associations with the CDCA4 protein. 
One of the first studies done to understand the anti-cancer 
effects of miR-15a was in 2009 where AKT-3 was 
determined as a novel direct target. In 2003 Stahl et al. 
determined that AKT-3 deregulation drove melanoma cell 
proliferation [25]. Moreover, in 2008 Cheung et al. discovered 
that AKT-3 works synergistically with V600E Braf to 
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exacerbate melanoma cell proliferation [26]. A 2009 study by 
Roccaro et al. then elucidated AKT-3 as a target of miR-15a 
in multiple myeloma [27]. Another discovery in 2013 by Luo 
et al. showed that miR-15a is able to inhibit breast cancer by 
targeting cyclin E1 (CCNE1) [28]. Cyclin E1 is able to 
regulate the G1 to S phase transition in the cell cycle by 
regulating the activity of CDK2, a protein whose activity is 
mandatory for progressing from the G1 to S phase [29]. This 
function of CDK2 has been known to be tumorigenic and 
makes cyclin E1 a desirable target for cancer treatment [30]. 
A 2015 study by Kang et al. showed that miR-15a 
displays anti-cancer activity by targeting Yes-associated 
protein 1 (YAP1) [31]. These results were determined through 
multiple experiments with gastric adenocarcinoma (GAC). 
Kang et al. found miR-15a to be downregulated in GAC cells 
and to have an inverse expression relationship with YAP1. 
YAP1 is a transcription factor that has several characteristics 
that make it a target of interest in cancer biology.  It has 
been shown that YAP1 plays an integral role in tumor cell 
survival by rescuing K-Ras, B-Raf, and PI3K inhibition [32]. 
This makes it an important protein to target as an adjuvant 
therapy with K-Ras, B-Raf, and PI3K inhibitors in cancer 
treatment. YAP1 also has been identified to antagonize 
contact inhibition when dephosphorylated by activity 
initiated through mitogenic growth factors, allowing nuclear 
localization and induction of CTGF expression [33]. 
In 2015 it was discovered that BCL2L2 is also targeted by 
miR-15a in non-small cell lung cancer [34]. This was further 
supported by results in 2016 that confirmed BCL2L2 as a 
target of miR-15a in HPV-positive hypopharyngeal 
squamous cell carcinoma [35]. BCL2L2 protein is in the 
BCL2 family and works as an anti-apoptotic molecule by 
preventing BH123 proteins from releasing cytochrome C 
from the mitochondria. These experiments were further 
proved by observing a reverse effect on cancer proliferation 
after the use of miR-15a inhibitors. In addition to targeting 
BCL2L2, miR-15a is able to induce apoptosis in some breast 
cancer cells by targeting γ-Synuclein (SNCG) [36]. 
γ-Synuclein is known to be correlated with poor prognosis in 
breast cancer, colon adenocarcinoma, oral squamous cell 
carcinoma, and bladder cancer [37-40]. The gene targets of 
miR-15a identified up to date and the effects of 
downregulating these target genes are demonstrated in Figure 
1. 
MiRNA is very effective and its abilities are far-reaching, 
with the ability to regulate up to 80% of the human genome 
[41]. In future studies, it is becoming more important that we 
find ways to use our information about the cancer 
microRNAome in translational research to determine 
effective and affordable clinical treatment plans. Much is 
known about the cancer microRNAome, but until we have a 
dependable way to treat cancer patients with miRNA, this 
knowledge is not reaching its full potential [6]. Currently, 
clinical trials are underway for several microRNAs in what is 
called “miRNA replacement therapy.” MiRNA mimics and 
expression vectors are used for the main method of delivery 
in this kind of therapy [42]. Unfortunately, miRNA mimics are 
Figure 1. The complete gene targets of miR-15a identified to date and the effects of downregulating these target genes. 
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expensive, have a short half-life in vivo, and have poor 
biodistribution; moreover, even though use of expression 
vectors is efficient, it has high toxicity and also creates 
immunogenic problems [43]. Fortunately, recent researchers 
have discovered more about how miRNA is transferred 
between cells. Using this information alongside the use of 
CRISPR interference (CRISPRi) to control the expression of 
miRNA, we may be able to provide cancer populations with 
translation control that will help regulate the cell cycle and 
decrease the malignancy of cancer populations.  
Our lab is currently working on an innovative technique 
that employs a variation of CRISPR/Cas9 to specifically 
target the promoter region of the miR-15a gene and other 
microRNA genes. CRISPR/Cas9 works as revolutionary 
genome-editing tool by synthesizing crRNA to target any 
specific position of the genome with relatively high fidelity 
[44]. This technique can be used to modify the genome or 
target the genome with transcription factors directly. 
CRISPRi is performed by conjugating transcription activator 
domains to a ‘dead’ (endonuclease-inactivated) version of 
Cas9, dCas9, thus enabling one to induce transcription of 
almost any gene, including miRNAs, in the genome [45]. The 
CRISPR system is quite affordable and costs only about 50 
USD per guide RNA and necessary components; old 
methods for genome targeting such as the zinc finger 
nucleases and TALENS required thousands of dollars and the 
laborious task of making custom proteins rather than guide 
RNAs [46, 47]. 
The CRISPR/Cas9 system by itself may not be the best 
method of action for fighting cancer mutations, though, 
because if even one cell is not successfully edited, the entire 
cancer population could be regenerated. On the other hand, 
with the new research done on understanding circulating 
microvesicles (CMVs), budded off cell fragments ranging 
from 100-1000 nm in diameter, miRNA is found to be passed 
between cells on a large scale [48-51]. Therefore, by inducing 
the transcription of anticancer miRNA in any significant 
number of cells, cancerous or not, all the cancerous cells will 
be saturated with the necessary translation-regulating 
miRNAs. In fact, clinical trials are in progress for using these 
microvesicles in the early detection of cancers; although, to 
date, there have been no other studies working with the 
cancer microRNAome on its combined use with 
CRISPR/Cas9 for the treatment of cancer cells [17, 52]. 
The novel idea of targeting the regulation of miRNA with 
CRISPRi presented here is hopeful because it provides a 
method of sustained regulation of gene expression across the 
entire cancer population so that small sub-populations are not 
able to regenerate the cancer cell population. As previously 
mentioned, this method of miRNA delivery will improve 
cost, efficacy, treatment frequency, miRNA stability, 
toxicity, biodistribution, and immunogenic problems. In 
order for this to work clinically, significant amounts of 
research will need to be done to improve the fidelity of 
CRISPR/Cas9 and observe the efficacy of this method in the 
lab under various circumstances [53]. It is our hope that 
significant progress will be made on this in the scientific and 
public community so that reliable, safe treatments for cancer 
patients can be provided at the soonest time possible. 
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